Genomic Health, Inc. (NASDAQ:GHDX) CEO Sells $1,846,250.00 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) CEO Kimberly J. Popovits sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $73.85, for a total value of $1,846,250.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Kimberly J. Popovits also recently made the following trade(s):

  • On Friday, August 9th, Kimberly J. Popovits sold 50,000 shares of Genomic Health stock. The shares were sold at an average price of $73.76, for a total value of $3,688,000.00.

GHDX stock traded down $0.31 during trading hours on Monday, hitting $73.12. 423,743 shares of the stock traded hands, compared to its average volume of 580,289. The firm has a 50-day moving average of $62.79. Genomic Health, Inc. has a one year low of $50.77 and a one year high of $92.18. The firm has a market capitalization of $2.73 billion, a P/E ratio of 69.64 and a beta of 1.06. The company has a current ratio of 5.74, a quick ratio of 5.67 and a debt-to-equity ratio of 0.17.



Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.07. Genomic Health had a return on equity of 19.51% and a net margin of 11.69%. The business had revenue of $114.14 million during the quarter, compared to analyst estimates of $110.78 million. During the same quarter last year, the company posted $0.23 EPS. Genomic Health’s revenue for the quarter was up 19.4% on a year-over-year basis. On average, equities research analysts anticipate that Genomic Health, Inc. will post 1.5 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in GHDX. Renaissance Technologies LLC boosted its position in shares of Genomic Health by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 2,814,500 shares of the medical research company’s stock valued at $163,719,000 after purchasing an additional 435,000 shares during the period. Norges Bank acquired a new position in shares of Genomic Health in the 4th quarter valued at $20,975,000. Fiera Capital Corp acquired a new position in shares of Genomic Health in the 1st quarter valued at $20,134,000. FMR LLC boosted its position in shares of Genomic Health by 83.8% in the 4th quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after purchasing an additional 251,085 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Genomic Health by 269.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 267,410 shares of the medical research company’s stock valued at $18,732,000 after purchasing an additional 194,988 shares during the period. Institutional investors and hedge funds own 95.15% of the company’s stock.

Several research analysts recently weighed in on GHDX shares. Deutsche Bank decreased their target price on Genomic Health from $80.00 to $55.00 and set a “hold” rating for the company in a research note on Thursday, May 30th. Canaccord Genuity cut Genomic Health from a “buy” rating to a “hold” rating and decreased their target price for the company from $77.00 to $72.00 in a research note on Tuesday, July 30th. Barclays raised Genomic Health from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $45.00 to $72.00 in a research note on Tuesday, July 30th. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a research note on Wednesday, July 31st. Finally, ValuEngine raised Genomic Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 27th. Nine investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Genomic Health presently has an average rating of “Hold” and an average price target of $69.86.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.